glp 1 gip 2ra glp-1/gip agonist Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide, and Glucagon Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Medication in New Liver Disease Nomenclature Dual GIP/GLP-1 receptor agonists: New

prepared the data, conducted the statistical analysis, and made the figures and tables

Its also critical to look into side effects with your physician, as both medications can cause nausea, digestive disturbances, and other side effects that might influence your choice

The body therefore tends to preserve fat stores while trimming unneeded muscle mass unless regular exercise signals that muscle remains necessary and adequate protein intake supports its maintenance

Some people may see steady progress within the first month, while others notice more gradual changes over several months

Step 4: If approved, review personalized treatment plan details, confirm medication preference (injection vs